ITDFinder is capable of detecting not only full-size ITD mutations including FLT3-ITD, but also PTD mutations, and offers significant potential for accurate clinical assessment of ITD mutations in AML patients, predicting prognostic risk, and optimizing therapy options. Here, FLT3 is linked to acute myeloid leukemia.